CJC-1295 No DAC + Ipamorelin 10mg

☆☆☆☆☆

This listing is for 1 × CJC-1295 No DAC + Ipamorelin 10mg vial only. This research peptide blend combines CJC-1295 No DAC, a GHRH analogue (5mg), with Ipamorelin, a selective GH secretagogue (5mg), for a total of 10mg in a single lyophilised formulation. Supplied for growth hormone release studies, pulsatile GH secretion research, and metabolic signalling investigations in experimental models. Specifications include ≥99% purity, lyophilised white powder form, and storage at -20°C (long-term).

Research Use Only: This product is strictly for laboratory research and is not intended for human or veterinary consumption, therapeutic use, diagnostic use, or clinical application.

Current Batch

SB26X7A2-CJC10Now Shipping

This batch has third party test results

4 Tests Available

Test Summary

Purity

99.90%

HPLC

Pass

Identity

Confirmed

LC-MS

Pass

Net Peptide Content

10.66 mg

Pass

Fentanyl Screen

Not Detected

Safety screen

Pass

Verified by ILS Laboratories|ISO/IEC 17025 Accredited

Official COA Verification

Independent Lab Verification

Scan the QR code to verify this certificate directly on the ILS Laboratories secure portal.

Access Code

SE3AK5V7

$99.95 AUD

Quantity

Product Overview

Understanding CJC-1295 No DAC + Ipamorelin 10mg

CJC-1295 No DAC + Ipamorelin 10mg is a dual-peptide research blend combining CJC-1295 No DAC, a GHRH analogue (5mg), with Ipamorelin, a selective GH secretagogue (5mg), in a single lyophilised formulation for in-vitro laboratory research. This combination enables investigation of synergistic GHRH and ghrelin receptor pathway activation, pulsatile GH secretion mechanisms, and multi-pathway growth hormone signalling in laboratory models. Products selected for website presentation meet Solatide Biosciences' ≥99% purity standard based on available third-party documentation.

Research Applications

•Pulsatile GH Secretion Research: Investigate combined GHRH and ghrelin receptor pathway activation and pulsatile growth hormone release mechanisms in vitro.
•Growth Hormone Release Studies: Study synergistic CJC-1295 and Ipamorelin receptor activation and downstream GH signalling cascade modulation in experimental models.
•Metabolic Signalling Investigations: Examine growth hormone pathway influences on metabolic signalling and downstream effector pathway regulation in cell-based assays.
•Comparative GHRH + Secretagogue Studies: Compare combination CJC-1295 + Ipamorelin activity against individual peptide controls in receptor pharmacology assays.
This analytical standard is strictly for in-vitro laboratory research use only.

Technical Specifications

Technical Parameter

Laboratory Specification

Purity

≥99% based on available third-party documentation

Composition

CJC-1295 No DAC 5mg + Ipamorelin 5mg

Total Content

10mg per vial

Appearance

White Lyophilised Powder

Storage

20°C (long-term)

Batch-specific third-party documentation available. Reports may include testing from independent laboratories such as Janoshik, Chromate, and Freedom Diagnostics, depending on the batch. View our COA & Lab Testing page for details.